Discover
GANX
Gain Therapeutics, Inc.
1.99
2 x 1.51
2 x 2.48
bid
ask
-
0.04
1.97%
2 @ 04:00 PM
1.95 -0.04 (2.01%)
| Ytd | -38.20% | |
| 1y | 26.75% |
1.92
day range
2.15
1.41
52 week range
4.34
| Open | 2.02 | Prev Close | 2.03 | Low | 1.92 | High | 2.15 | Mkt Cap | 84.88M |
| Vol | 1.49M | Avg Vol | 843.50K | EPS | -0.58 | P/E | N/A | Forward P/E | -1.76 |
| Beta | 0.34 | Short Ratio | 1.65 | Inst. Own | 7.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.82 | 200-d Avg | 2.20 | 1yr Est | 7.33 |
GANX News
benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
benzinga.com
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,
globenewswire.com
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Developmen
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,